|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Drug resistance to molecular targeted therapyand its consequences for treatment decisions in non-small-cell lung cancer 显示文摘 | Spaans JN Goss GD | 2014 | Front Oncol2014，4，： | 1 |
| 2 | Combination chemotherapy with teniposide (VM26) and carboplatin in small cell lung cancer显示文摘 | Goss GD Vincent M Germond C | 1993 | Am J Clin Oncol1993，16，4： | 1 |
| 3 | Randomized, double- blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study显示文摘 | Goss GD Arnold A Shepherd FA | 2010 | J Clin Oncol2010，28，1： | 1 |
| 4 | Randomized,double blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer:NCIC clinical trials group BR24 Study显示文摘 | Goss GD Arnold A Shepherd FA | | 0，，01： | 1 |
| 5 | Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BRI9 study显示文摘 | Goss GD O'Callaghan C Lorimer l | 2013 | J Clin Oncol2013，31，27： | 1 |
| 6 | Non-smal-celllung can-cer:then and now显示文摘 | Schil er JH Gandara DR Goss GD | | 0，，08： | 1 |
| 7 | Gefitinib versus placebo in completely resected non-small-cell lung cancer:results of the NCIC CTG BR19 study显示文摘 | Goss GD OCallaghan C Lorimer I | 2013 | J Clin Oncol2013，31，27： | 1 |
| 8 | Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCTG clinical trials group BR24 smdy显示文摘 | Goss GD Arnold A Shepherd FA | 2010 | J Clin Oncol2010，28，1： | 1 |
| 9 | Randomized,double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced Non-small-cell lung cancer:NCIC Clinical Trials Group BR24 Study显示文摘 | Goss GD Arnold A Shepherd FA | 2010 | J Clin Oncol2010，28，1： | 1 |
| 10 | Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer显示文摘 | TAN EH GOSS GD SALGIA R | 2011 | J Thorac Oncol2011，6，8： | 1 |
| 11 | A phase Ⅲ randomized,double-blind,placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinib in completely resected stageIB-ⅢA Non-small Cell Lung Cancer(NSCLC):NCICCTGBR显示文摘 | Goss GD Lorimer I Tsao MS | 2010 | J Clin Oncol2010，28，18： | 1 |
| 12 | A phase Ⅲ prospective randomized,double-blind,placebo-controlled trial of the epidermal growth factor receptoy inhibitor,gefitinib in completely resected stage Ⅰ B-Ⅲ A non smsll cell lung cancer (NSCLC),NCIC CTG BR 19显示文摘 | Goss GD Lorimer I Tsao MS | | 0，，： | 1 |
| 13 | The effect of low-molecular-weight heparin on cancer survival:A systematic review and meta-analysis of randomized trials显示文摘 | Lazo-Langner A Goss GD Spaans JN | 2007 | Thromb Haemost2007，5，4： | 1 |
| 14 | Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCI'C clinical trials group BR24 smdy显示文摘 | Goss GD Arnold A Shepherd FA | 2010 | J Clin Oncol2010，28，1： | 1 |
| 15 | Bisphosphonates and avascularnecrosis of the jaw:a possible association显示文摘 | Carter GD Goss AN Doecke C | 2005 | Med J Aust2005，182，： | 1 |
| 16 | Non-small cell lung cancer: then and now显示文摘 | Schiller JH Gandara DR Goss GD | 2013 | J Clin Oneol2013，31，8： | 1 |
| 17 | Gefitinib versus placebo in completely resected non-small-cell lung cancer: Results of the NCIC CTG BR19 study显示文摘 | Goss GD O'Callaghan C Lorimer I | 2013 | J Clin Oncol2013，31，27： | 1 |
| 18 | Tumor vasculature as a therapeutic target in non- small cell lung cancer显示文摘 | Bar J Goss GD | 2012 | J Thorac Oncol2012，7，3： | 1 |
| 19 | Physiological and clinical aspects of vitamin A and its metabolites显示文摘 | Goss GD MeBurney MW | 1992 | Crit Rev Clin Lab Sci1992，29，34： | 1 |
| 20 | The effect of low-mole-cular-weight heparin on cancer survival显示文摘 | Lazo-Langner A Goss GD Spaans JN | 2007 | Thromb Haemost2007，5，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员